Serum paraoxonase/arylesterase activity and oxidative stress status in children with metabolic syndrome

JCRPE Journal of Clinical Research in Pediatric Endocrinology

Volumn 6, Issue 3, 2014, Pages 163-168

  Eren, Erdal ^a   Abuhandan, Mahmut ^a   Solmaz, Abdullah ^a   Taşkın, Abdullah ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Metabolic syndrome; Obesity; Oxidative stress; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; OXIDIZING AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; PON1 PROTEIN, HUMAN;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY MASS; CHILD; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; SCHOOL CHILD; WAIST CIRCUMFERENCE; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; PEDIATRIC OBESITY; PREDICTIVE VALUE; RISK FACTOR; UPREGULATION;

ADOLESCENT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; OXIDATIVE STRESS; PEDIATRIC OBESITY; PREDICTIVE VALUE OF TESTS; RISK FACTORS; UP-REGULATION;

EID: 84908218387     PISSN: 13085727     EISSN: 13085735     Source Type: Journal    
DOI: 10.4274/jcrpe.1454     Document Type: Article

References (34)

1. Morrison JA, Friedman LA, Gray-McGuire C. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: The Princeton Lipid Research Clinics Follow-up Study. Pediatrics 2007;120:340-345.
2. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: Contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999;892:146-154.
3. McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Arterioscler Thromb Vasc Biol 1995;15:431-440.
4. Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg 2008;70:193-219.
5. Galassetti P. Inflammation and oxidative stress in obesity, metabolic syndrome and diabetes. Exp Diabetes Res 2012;2012:943706.
6. Korkmaz GG, Altınoglu E, Civelek S, Sozer V, Erdenen F, Tabak O, Uzun H. The association of oxidative stress markers with conventional risk factors in the metabolic syndrome. Metabolism 2013;62:828-835. Epub 2013 Feb 11
7. Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:1545-1550. Epub 2006 Apr 20
8. Garin MC, Kalix B, Morabia A, James RW. Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab 2005;90:2264-2269. Epub 2005 Feb 1
9. Martinelli N, Girelli D, Olivieri O, Guarini P, Bassi A, Trabetti E, Friso S, Pizzolo F, Bozzini C, Tenuti I, Annarumma L, Schiavon R, Franco Pignatti P, Corrocher R. Novel serum paraoxonase activity assays are associated with coronary artery disease. Clin Chem Lab Med 2009;47:432-440.
10. Akçay AB, Camsarı A, Ozcan T, Ciçek D, Akkuş N, Seyis S, Cimen B, Celebi B, Döven O, Cin G. The relationship between paraoxonase-1 activity and coronary artery disease in patients with metabolic syndrome. Turk Kardiyol Dern Ars 2011;39:371-377.
11. Barlow SE; Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: Summary report. Pediatrics 2007;120(Suppl 4):164-192.
12. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – A new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 2006;23:469-480.
13. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL. 2000 CDC growth charts for the United States: Methods and development. National Center for Health Statistics. Vital Health Stat 11 2002;246:1-190.
14. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112-119.
15. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103-1111. Epub 2005 Oct 7
16. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992;30:391-395.
17. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-1138.
18. Bajnok L, Seres I, Varga Z, Jeges S, Peti A, Karanyi Z, Juhasz A, Csongradi E, Mezosi E, Nagy EV, Paragh G. Relationship of serum resistin level to traits of metabolic syndrome and serum paraoxonase 1 activity in a population with a broad range of body mass index. Exp Clin Endocrinol Diabetes 2008;116:592-599. Epub 2008 May 9
19. Tabur S, Torun AN, Sabuncu T, Turan MN, Celik H, Ocak AR, Aksoy N. Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation. Eur J Endocrinol 2010;162:535-541. Epub 2009 Dec 18
20. Seres I, Paragh G, Deschene E, Fulop TJr., Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 2004;39:59-66.
21. Koncsos P, Seres I, Harangi M, Páll D, Józsa L, Bajnok L, Nagy EV, Paragh G. Favorable effect of short-term lifestyle intervention on human paraoxonase-1 activity and adipokine levels in childhood obesity. J Am Coll Nutr 2011;30:333-339.
22. Seres I, Bajnok L, Harangi M, Sztanek F, Koncsos P, Paragh G. Alteration of PON1 activity in adult and childhood obesity and its relation to adipokine levels. Adv Exp Med Biol 2010;660:129-142.
23. Ferré N, Feliu A, García-Heredia A, Marsillach J, París N, Zaragoza-Jordana M, Mackness B, Mackness M, Escribano J, Closa-Monasterolo R, Joven J, Camps J. Impaired paraoxonase-1 status in obese children. Relationships with insülin resistance and metabolic syndrome. Clin Biochem 2013;46:1830-1836. Epub 2013 Sep 10
24. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7:69-76.
25. Lee JH, Park JH, Lee SH, Kim JR, Cho KH. Elevated HDL2- paraoxonase and reduced CETP activity are associated with a dramatically lower ratio of LDL-cholesterol/total cholesterol in a hypercholesterolemic and hypertriglyceridemic patient. Int J Mol Med 2010;25:945-951.
26. Faienza MF, Francavilla R, Goffredo R, Ventura A, Marzano F, Panzarino G, Marinelli G, Cavallo L, Di Bitonto G. Oxidative stress in obesity and metabolic syndrome in children and adolescents. Horm Res Paediatr 2012;78:158-164. Epub 2012 Oct 10
27. Molnár D, Decsi T, Koletzko B. Reduced antioxidant status in obese children with multimetabolic syndrome. Int J Obes Relat Metab Disord 2004;28:1197-1202.
28. Pirgon Ö, Bilgin H, Çekmez F, Kurku H, Dündar BN. Association between insulin resistance and oxidative stress parameters in obese adolescents with non-alcoholic fatty liver disease. J Clin Res Pediatr Endocrinol 2013;5:33-39.
29. Torun E, Gökçe S, Ozgen LT, Aydın S, Cesur Y. Serum paraoxonase activity and oxidative stress and their relationship with obesityrelated metabolic syndrome and non-alcoholic fatty liver disease in obese children and adolescents. J Pediatr Endocrinol Metab 2014;27:667-675.
30. Semiz S, Rota S, Ozdemir O, Ozdemir A, Kaptanoğlu B. Are C-reactive protein and homocysteine cardiovascular risk factors in obese children and adolescents? Pediatr Int 2008;50:419-423.
31. Akinci G, Akinci B, Coskun S, Bayindir P, Hekimsoy Z, Ozmen B. Evaluation of markers of inflammation, insulin resistance and endothelial dysfunction in children at risk for overweight. Hormones (Athens) 2008;7:156-162.
32. Steene-Johannessen J, Kolle E, Reseland JE, Anderssen SA, Andersen LB. Waist circumference is related to low-grade inflammation in youth. Int J Pediatr Obes 2010;5:313-319.
33. Kitsios K, Papadopoulou M, Kosta K, Kadoglou N, Papagianni M, Tsiroukidou K. High-sensitivity C-reactive protein levels and metabolic disorders in obese and overweight children and adolescents. J Clin Res Pediatr Endocrinol 2013;5:44-49. Epub 2013 Jul 1
34. Soriano-Guillén L, Hernández-Garca B, Pita J, Domínguez Garrido N, Del Río-Camacho G, Rovira A. High-sensitivity C-reactive protein is a good marker of cardiovascular risk in obese children and adolescents. Eur J Endocrinol 2008;159:1-4. Epub 2008 May 1